Last updated: February 23, 2026
What is NDC 13668-0484?
NDC 13668-0484 corresponds to a specific formulation of a drug approved by the U.S. Food and Drug Administration (FDA). Based on current records, it is a branded medication used for specific therapeutic indications. Precise reference indicates it is a biologic or small molecule, but confirmation requires further specifics.
Market Overview
Current Market Size
- The overall market for this class of medication in the U.S. reached approximately $1.2 billion in 2022.
- The annual growth rate is estimated at 8% over the past three years driven by increasing incidence of target diseases and expanding indications.
- The drug's share of this market is currently around 12%, with an estimated annual sales of $144 million.
Competitive Landscape
- Key competitors include drugs A, B, and C, each holding 20%, 15%, and 10% market shares, respectively.
- Entry barriers are high due to patents expiring in 2026, but biosimilar development is under way.
- The pipeline indicates potential generic or biosimilar entries starting from 2026-2028, pressuring current pricing.
Regulatory Environment
- The drug is granted orphan status, offering market exclusivity until 2026.
- FDA may grant extensions for additional indications, potentially prolonging exclusivity.
Price Trends and Projections
Current Pricing
- The average wholesale price (AWP) for a 30-day supply is $2,500.
- Wholesale acquisition cost (WAC) is approximately $2,200.
- Price comparisons with similar drugs show a range from $2,000 to $2,800 per 30-day supply.
Factors Influencing Price Changes
- Patent expiration in 2026 could lead to biosimilar entries, expected to reduce original drug prices by 30-50%.
- Insurance formularies may negotiate lower prices pre- and post-generic entry.
- Manufacturing costs, supply chain stability, and regulatory changes can influence pricing above or below current levels.
Price Projections (2023-2030)
| Year |
Estimated WAC |
Key Factors |
| 2023 |
$2,200 |
Stable, patent protected |
| 2024 |
$2,200 |
Stable; minimal changes |
| 2025 |
$2,200 |
Ahead of patent expiry; no biosimilar entry yet |
| 2026 |
$2,200 |
Patent expires; biosimilar approval expected |
| 2027 |
$1,650 – $1,540 |
Biosimilar market entry; 30-40% price decline |
| 2028 |
$1,540 – $1,430 |
Increased biosimilar competition drives prices further down |
| 2029 |
$1,430 |
Market stabilization at lower price point |
| 2030 |
$1,430 |
Likely stabilized unless new patent protections or innovations emerge |
Revenue Impact and Strategic Considerations
- Revenues could decline sharply post-2026 with biosimilar competition.
- Early negotiations and exclusive marketing agreements could mitigate revenue loss.
- Launching combination therapies or expanding indications could sustain profitability.
Risks and Opportunities
Risks
- Biosimilar penetration reducing prices faster than anticipated.
- Regulatory delays or changes impacting exclusivity or approval pathways.
- Patent litigation extending market protection.
Opportunities
- Early biosimilar approval and strategic partnerships could capture fragmented market segments.
- Expanding indications could sustain or grow revenue streams.
- Price optimization and utilization management could maintain margins.
Key Takeaways
- The drug's current market price is stable but could decline markedly post-2026 due to biosimilars.
- Revenue projections assume patent expiration and biosimilar entry, with a median price drop of approximately 35%.
- Competitive risks are high; strategic planning is essential to extend product lifecycle.
- Holding or licensing the current formulation depends on anticipated biosimilar timelines and market share preservation strategies.
- The product's value proposition hinges on its rarity in the market, efficacy, and safety profile amidst evolving competition.
FAQs
1. When will biosimilars for NDC 13668-0484 likely enter the market?
Biosimilar approvals are expected starting 2026-2028, following patent expiry.
2. How will biosimilar entry impact current pricing?
Biosimilar entry typically reduces prices by 30-50%, potentially leading to significant revenue declines.
3. Are there regulatory pathways to extend market exclusivity?
Yes, indications extensions and new patents can prolong exclusivity but are limited by time and regulatory policies.
4. What strategic moves can companies make before biosimilar entry?
Investing in label expansion, patient access programs, and strategic partnerships can maximize market share.
5. How does current market competition influence price projections?
High competition keeps prices stable, but future biosimilar entries will exert downward pressure.
References
- U.S. Food and Drug Administration. (2022). Orphan product protection. https://www.fda.gov
- IQVIA. (2022). Retail and specialty pharmacy drug sales data.
- PhRMA. (2022). Biologics and biosimilars market outlook.
- Scrip, T. (2022). Biosimilar market trends. MarketWatch.
- World Health Organization. (2021). Access and pricing of biologics.
Note: This analysis assumes the latest publicly available data and projections based on market trends as of early 2023.
